Investors are scratching their heads about the brouhaha being made over the spin-out of Exosome Science, Inc. by AEMD. I think the question is more appropriately… “what effect would ESI have on AEMD if the diagnostic firm were worth $140 million in the market and AEMD still owned 50%”....for free.
The moves by AEMD are most interesting….provocative. We are all aware of the lack of published success the Company has not released regarding their Indian, HCV therapeutic efforts. Also, there has been nothing but “dead silence” regarding any movement in the cancer arena. Yet, we do have real and strong evidence that the device and science works (a la the continued work with Battelle and NxStage) and that it is interesting enough for the US Government to invest more money after the initial, 2011 round. Also, it has to be considered encouraging that the FDA is permitting AEMD with an IDE to test the device for safety and efficacy re HCV. Best of all, we now have news about the important association with one of the top, if not the top, exosome research scientists in the world.